Fibrin Sealants Market By Product Type (Liquid Fibrin Sealants, Patch-Based Sealants, Sprayable Sealants); By Application (General Surgery, Cardiovascular Surgery, Orthopedic Surgery, Liver and Transplant Surgery, Neurosurgery); By End User (Hospitals and Surgical Centers, Specialty Clinics, Military and Field Hospitals); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Fibrin Sealants Market  – (Updated On: 31-Aug-2026)

Fibrin Sealants Market Size, Surgical Role and 2032 Commercial Outlook

The Global Fibrin Sealants Market was valued at USD 1.48 billion in 2025 and is projected to reach USD 2.39 billion by 2032, expanding at a CAGR of 7.1% during 2026–2032, according to Strategic Market Research.

 

The fibrin sealants market is based on biologic surgical products that combine fibrinogen and thrombin at the treatment site to form a local fibrin clot and help control bleeding and seal tissue when conventional techniques are insufficient. Baxter markets TISSEEL, a fibrin sealant used as an adjunct to hemostasis when sutures, ligatures, or cautery are ineffective or impractical. Ethicon (Johnson & Johnson MedTech) offers EVICEL, a human fibrin sealant used to support surgical hemostasis.

 

Recent advances in fibrin sealant technology are centered on faster preparation, easier application, and improved surgical hemostasis. Ready-to-use systems such as VISTASEAL use pre-filled syringes and spray applicators for rapid, consistent delivery, while EVARREST combines fibrinogen and thrombin within an absorbable patch for direct tissue sealing. Autologous point-of-care thrombin systems are also emerging, alongside improved fractionation and pathogen-reduction processes that enhance product safety, stability, and adoption across complex surgeries, skin grafting, and bleeding-control procedures.

 

Market Snapshot: Segment Leaders and Fast-Growth Pockets

Product Type Segments

• Liquid fibrin sealants held 55% of the market in 2025, representing USD 0.814 billion, and are projected to expand at a CAGR of 6.4%; they remain the largest product configuration because surgeons can control volume and coverage across varied operative surfaces.

• Patch-based sealants accounted for 28% and USD 0.414 billion in 2025 and are forecast at a CAGR of 7.7%; their role is strongest at focal bleeding sites where an absorbable matrix and manual compression can be combined.

• Sprayable sealants represented 17% and USD 0.252 billion in 2025 and are projected to grow at a CAGR of 8.5%; the segment benefits from broad-surface coverage and minimally invasive delivery, with SMR classifying revenue by predominant commercial delivery configuration to avoid double counting with standard liquid systems.

 

Application Segments

• General surgery led with 30% and USD 0.444 billion in 2025 and a CAGR of 6.5%, reflecting broad use across abdominal, colorectal, bariatric, urologic and soft-tissue procedures.

• Cardiovascular surgery accounted for 24% and USD 0.355 billion and is forecast at a CAGR of 7.2%, supported by high-value use around vascular sutures, grafts and anticoagulated patients.

• Orthopedic surgery represented 19% and USD 0.281 billion and is projected at a CAGR of 7.4%, supported by arthroplasty and spine-related bleeding-management needs but constrained by competing hemostatic and blood-conservation strategies.

• Liver and transplant surgery held 15% and USD 0.222 billion and is forecast at a CAGR of 8.0%, reflecting difficult parenchymal bleeding and the resource intensity of transplant and hepatobiliary procedures.

• Neurosurgery accounted for 12% and USD 0.178 billion and is expected to record the fastest application CAGR of 8.3%, supported by precision hemostasis and selected tissue-sealing applications.

 

End-User Segments

• Hospitals and surgical centers dominated with 76% and USD 1.125 billion in 2025 and a CAGR of 6.8%, reflecting the concentration of complex surgery and formal value-analysis procurement in this channel.

• Specialty clinics held 16% and USD 0.237 billion and are projected at a CAGR of 7.8%, with use concentrated in reconstructive, burn, dental and other specialist procedures where a defined adhesion or sealing role exists.

• Military and field hospitals represented 8% and USD 0.118 billion and are forecast at a CAGR of 9.2%; this SMR channel includes defense hospitals, deployed surgical units and field/trauma facilities, and is treated separately from civilian hospitals and ASCs.

 

Regional Segments

• North America led with 38% and USD 0.562 billion in 2025 and a CAGR of 6.4%, supported by a broad licensed portfolio and large inpatient and outpatient surgical infrastructure.

• Europe accounted for 28% and USD 0.414 billion and is projected at a CAGR of 6.7%, supported by mature surgical use, public procurement and established fibrin-patch utilization.

• Asia Pacific represented 24% and USD 0.355 billion and is forecast at the fastest regional CAGR of 8.5%, supported by expanding complex-surgery capacity and stronger regional plasma-product manufacturing.

• Latin America held 6% and USD 0.089 billion and is projected at a CAGR of 7.6%, with utilization concentrated in tertiary hospitals and private surgical networks.

• Middle East & Africa accounted for 4% and USD 0.059 billion and are forecast at a CAGR of 7.4%, with use concentrated in advanced referral hospitals, trauma programs and complex surgical centers.

 

SMR Market Definition and Sizing Boundary

Strategic Market Research defines the fibrin sealants market as commercial fibrinogen-thrombin products used for surgical hemostasis, tissue sealing or tissue adherence, including standard liquid systems, spray-configured delivery systems and active fibrin patches. The scope excludes standalone thrombin products, gelatin-thrombin matrices, oxidized cellulose, collagen-only hemostats, synthetic polyethylene-glycol sealants, cyanoacrylates and external skin adhesives. Autologous fibrin-preparation platforms are included where they generate a fibrin sealant for operative use.

The product-type segmentation is a commercial delivery classification rather than a claim that sprayable fibrin sealants have different underlying clotting chemistry from liquid sealants. Where the same fibrin formulation can be dripped or sprayed, SMR allocates revenue according to the predominant marketed delivery configuration or procurement SKU used in the model. This rule preserves the supplied 55% liquid, 28% patch and 17% sprayable split without counting the same revenue twice. VISTASEAL illustrates why this distinction matters: its FDA labeling allows both dripping and spraying, and its kit includes dedicated airless spray tips. [5] [36]

For end users, “hospitals and surgical centers” includes civilian acute-care hospitals, hospital outpatient departments and ambulatory surgical centers. Specialty clinics are physician- or specialty-led facilities outside this core channel. Military and field hospitals are separately sized as defense medical centers, deployed surgical hospitals and field/trauma facilities. All segment and regional values are Strategic Market Research estimates derived from the USD 1.48 billion 2025 market baseline; displayed values are rounded and may differ by USD 0.001 billion from exact multiplication.

 

Liquid, Patch and Spray Platforms Reshape Surgical Hemostasis

Product Type

Liquid fibrin sealants accounted for 55% of the market, representing USD 0.814 billion in 2025, and are projected to expand at a CAGR of 6.4% during 2026–2032. Their leadership reflects flexibility across open and minimally invasive procedures, adjustable dosing and established hospital familiarity. Baxter’s TISSEEL is licensed as an adjunct to hemostasis in adult and pediatric patients when conventional surgical techniques are ineffective or impractical. VISTASEAL adds a second large liquid platform, combining human fibrinogen and thrombin and allowing drip or spray application; its 2024 pediatric expansion also increases the number of departments that can standardize on the same core platform. [3] [5] [6]

Patch-based sealants held 28% of the market, equivalent to USD 0.414 billion in 2025, and are forecast to grow at a CAGR of 7.7%. Patches are commercially differentiated where the surgeon can directly cover a defined bleeding surface and apply compression. EVARREST combines human fibrinogen and thrombin in an absorbable composite patch for adult surgical hemostasis, while TachoSil is indicated in the United States for adult and pediatric cardiovascular and hepatic surgery. Corza’s 2024 acquisition of the TachoSil manufacturing operation adds supply-chain control to the competitive position of the patch platform. [7] [8] [24]

Sprayable sealants represented 17% of the market, corresponding to USD 0.252 billion in 2025, and are projected to record a CAGR of 8.5%. Their value proposition is broad and relatively uniform application over irregular surfaces, with delivery technology becoming a meaningful part of product differentiation. VISTASEAL’s airless spray tips and dedicated laparoscopic applicator show how manufacturers can extend an established biologic into open and minimally invasive workflows without changing the underlying fibrinogen-thrombin mechanism. [5] [36]

 

Application

General surgery accounted for 30% of the market, representing USD 0.444 billion in 2025, and is projected to expand at a CAGR of 6.5%. The segment benefits from a wide procedural base in abdominal, colorectal, bariatric, urologic and soft-tissue surgery. A U.S. Premier Healthcare database study recorded 80,628 uses of TISSEEL fibrin sealant solution from January 2018 through September 2020; 49.5% of those uses fell within the study’s combined abdominal/pelvic grouping, which included general, urologic, bariatric and obstetric/gynecologic procedures. This utilization evidence supports the breadth of the application but should not be read as an independent validation of SMR’s 30% global general-surgery share. [15]

Cardiovascular surgery held 24% of the market, equivalent to USD 0.355 billion in 2025, and is forecast to grow at a CAGR of 7.2%. Anticoagulation, vascular anastomoses, graft surfaces and the high cost of prolonged bleeding make this one of the most economically consequential applications. A systematic review of 21 vascular and cardiac studies involving 7,622 patients found a mean 120.7 mL reduction in blood loss and a 2.5-minute reduction in time to hemostasis with fibrin- and thrombin-based sealants, but no significant reduction in postoperative transfusion, bleeding-related reoperation or 30-day mortality. The evidence supports selective, procedure-specific use rather than routine use across every cardiovascular case. [17]

Orthopedic surgery represented 19% of the market and USD 0.281 billion in 2025 and is projected to expand at a CAGR of 7.4%. Arthroplasty, spine and complex reconstruction create bleeding-management opportunities, but fibrin systems compete with tranexamic-acid protocols, cautery, gelatin matrices, cellulose products and other topical agents. In the Premier utilization study, 24% of recorded TISSEEL uses occurred in a combined orthopedic, neurologic and spine category; because that dataset combines specialties, it is used here only as evidence of cross-specialty utilization and not as a standalone orthopedic market-share measure. [15]

Liver and transplant surgery accounted for 15% of the market, corresponding to USD 0.222 billion in 2025, and is projected to grow at a CAGR of 8.0%. Highly vascular parenchymal tissue can generate diffuse bleeding that is difficult to control with sutures alone, making surface-directed hemostasis particularly relevant. TachoSil’s U.S. indication explicitly includes hepatic surgery, while VeraSeal studies in organ surgery demonstrated rapid hemostatic control against oxidized regenerated cellulose. The broader procedural base is substantial: the WHO-linked Global Observatory on Donation and Transplantation reported a record 173,727 solid-organ transplants worldwide in 2024, including 42,497 liver transplants. [8] [18] [33]

Neurosurgery held 12% of the market, representing USD 0.178 billion in 2025, and is forecast to expand at a CAGR of 8.3%. Product choice is influenced by confined anatomy, the need for controlled application and whether the clinical objective is hemostasis, tissue sealing or both. TachoSil’s European authorization includes supportive sealing of the dura mater in adults to help prevent postoperative cerebrospinal-fluid leakage, whereas the U.S. label is narrower; this difference illustrates why regional indication breadth can materially affect commercial opportunity. [8] [18]

 

Surgical Bleeding Economics and the Clinical Case for Fibrin Sealants

The market is not driven by surgery counts alone; the commercially relevant pool is the subset of procedures in which bleeding is difficult, costly or operationally disruptive. A 2025 retrospective Premier Healthcare analysis of 119,994 adult patients who received hemostatic agents found disruptive surgical bleeding in 10.8% of cases. Across bariatric, colorectal, spine, total hip arthroplasty and total knee arthroplasty, disruptive bleeding was associated with USD 3,377–23,346 of additional hospital cost and 1.0–4.9 additional hospital days; operating-room time increased by 42.3–62.4 minutes in bariatric, colorectal and spine surgery. The study was funded by Johnson & Johnson and several authors were company employees, so SMR uses it as evidence of bleeding-related resource burden rather than proof of the economic value of a specific fibrin product. [16]

Clinical evidence is strongest when interpreted at the procedure and endpoint level. EMA summarizes three main VeraSeal studies in 614 mainly adult patients: in vascular surgery, 76% of patients had no bleeding four minutes after VeraSeal versus 23% after manual compression, while in organ surgery 93% achieved the endpoint versus 81% with Surgicel. A fourth study in 178 children and adolescents reported the four-minute endpoint in 97% of VeraSeal recipients and 95% of Evicel recipients. These results help support formulary breadth, but they should not be generalized into claims of lower mortality, transfusion or total episode cost without procedure-specific evidence. [18]

The clinical evidence therefore supports a market in which fibrin sealants are purchased for defined problems rather than used as universal replacements for conventional techniques. Faster local hemostasis, access to irregular tissue surfaces, the ability to combine biologic clot formation with a patch matrix, and compatibility with minimally invasive applicators are commercially meaningful. The limiting factor is that hospitals increasingly distinguish a strong local hemostasis endpoint from evidence of fewer transfusions, complications, readmissions or reoperations.

 

Hospital Procurement, Pack Economics and Care-Setting Shift

Hospitals and surgical centers accounted for 76% of the market, representing USD 1.125 billion in 2025, and are projected to expand at a CAGR of 6.8%. This channel includes acute-care hospitals, hospital outpatient departments and civilian ASCs, where fibrin products compete for formulary position through clinical indication, preparation time, applicator workflow, pack size, storage, wastage, surgeon familiarity, supply reliability and contract price. Baxter’s 2025 Form 10-K reported USD 1.198 billion of Advanced Surgery sales, but that category includes the company’s broader hemostat, sealant and adhesion-prevention portfolio and is not treated by SMR as fibrin-sealant revenue. [23]

A 2026 Freedom of Information response from East Sussex Healthcare NHS Trust provides unusually concrete procurement evidence. The trust reported GBP 211,615 of fibrin-product expenditure during calendar 2025 and listed Tisseel Lyo, VeraSeal and a slow-setting flowable fibrin sealant. Reported utilization totaled 493 units across multiple presentations, including 4 mL and 10 mL packs. The example is not extrapolated into global market share; its value is that it shows hospitals can maintain multiple fibrin formulations and pack sizes simultaneously, making waste, handling and procedure fit part of the commercial decision. [22]

Specialty clinics held 16% of the market, equivalent to USD 0.237 billion in 2025, and are forecast at a CAGR of 7.8%. The segment is concentrated in reconstructive, burn, dental and other specialist procedures where a product has a specific adherence or sealing role. ARTISS is a useful example because its FDA label covers adherence of autologous skin grafts to burn wound beds and adherence of tissue flaps during facial rhytidectomy, while explicitly stating that it is not indicated as an adjunct to hemostasis. This makes it commercially distinct from TISSEEL even though both are fibrin sealants from Baxter. [4]

Military and field hospitals represented 8% of the market, corresponding to USD 0.118 billion in 2025, and are projected to record a CAGR of 9.2%. This is an SMR-defined institutional channel covering defense medical centers, deployed surgical hospitals and field/trauma facilities. The opportunity is most credible for products and configurations that reduce setup burden and support rapid topical bleeding control; however, unlike civilian hospital procurement, there is no single public government dataset that directly reports global fibrin-sealant expenditure for this channel, so the share should be presented as an SMR market estimate rather than a government-reported utilization statistic.

Outpatient migration raises the importance of pack and workflow economics. MedPAC reported 6,436 Medicare-certified ASCs, 3.4 million fee-for-service users and 6.4 million surgical procedures in 2024. CMS expanded the ASC Covered Procedures List for 2026 by adding 289 procedures under revised criteria plus 271 codes removed from the inpatient-only list. Under OPPS, CMS can package integral, ancillary, supportive and adjunctive items into the primary service payment. These payment structures make total case economics more important than the unit price of a fibrin sealant alone. [19] [20] [21]

 

Regional Growth Hotspots and Access Dynamics

North America accounted for 38% of the market, representing USD 0.562 billion in 2025, and is projected to expand at a CAGR of 6.4%. The region combines a large operative base with several current FDA-licensed fibrin platforms. Baxter’s TISSEEL and ARTISS, Grifols-manufactured VISTASEAL distributed by Ethicon, EVARREST and TachoSil create a differentiated mix of liquid, adherence and patch products. The September 2024 VISTASEAL pediatric expansion broadens the platform’s addressable patient population, while the discontinued U.S. status of EVICEL and RAPLIXA presentations shows that commercial competition is more concentrated than the historical FDA approval list alone suggests. [2] [6] [9] [10]

Europe held 28% of the market, equivalent to USD 0.414 billion in 2025, and is forecast to grow at a CAGR of 6.7%. The region combines high surgical activity with national and hospital-level procurement. England recorded 13.0 million finished consultant episodes with a procedure or intervention in April 2024–March 2025, while Germany recorded 16.31 million inpatient operation codes in 2024. VeraSeal and TachoSil have established European positions, but the July 2024 EU withdrawal of EVICEL for commercial reasons demonstrates that mature regional access does not guarantee indefinite portfolio retention. [13] [14] [11] [18]

Asia Pacific represented 24% of the market, corresponding to USD 0.355 billion in 2025, and is projected to record the fastest regional CAGR of 8.5%. The competitive structure differs from North America because regional plasma manufacturers can compete through local supply and established blood-product infrastructure. Reliance Life Sciences markets ReliSeal in India; KM Biologics supplies BOLHEAL in Japan; CSL lists Beriplast P Combi-Set across several Asian markets; and Shanghai RAAS lists FIBINGLURAAS Human Fibrin Sealant Kit as part of a vertically integrated plasma portfolio. Shanghai RAAS reported 55 plasma donation centers by July 2025, illustrating the upstream scale that can support domestic plasma-derived products in China. [28] [29] [30] [31] [32]

Latin America held 6% of the market, representing USD 0.089 billion in 2025, and is projected to grow at a CAGR of 7.6%. Utilization is concentrated in tertiary hospitals, private surgical networks, transplant centers and cardiovascular programs in larger markets. CSL’s global product list shows Beriplast P Combi-Set availability in Argentina, Brazil, Chile and Colombia, illustrating the importance of country-specific registration and distributor reach rather than a single uniform regional portfolio. [30]

Middle East & Africa accounted for 4% of the market, equivalent to USD 0.059 billion in 2025, and are forecast to expand at a CAGR of 7.4%. The commercial base is concentrated in tertiary referral hospitals, trauma centers and complex surgical programs, with Gulf markets offering the strongest premium-product opportunity. Wider penetration remains sensitive to specialist availability, biologic supply logistics, hospital budgets and uneven access to advanced surgery; for this region, these structural factors are more important than broad disease prevalence statistics that do not translate directly into fibrin-sealant purchasing.

 

Competitive Product Map: Active Platforms, Legacy Exits and Portfolio Positioning

Competition is concentrated among plasma-derived biologics manufacturers, diversified biosurgery companies and specialist fibrin-platform suppliers. Companies compete through product format, indication breadth, preparation and storage, applicator design, hospital contracting, supply reliability, geographic commercialization and the strength of procedure-specific evidence. Public company filings rarely isolate fibrin-sealant revenue from broader biosurgery portfolios, so Strategic Market Research does not assign company market shares from public sales disclosures.

Product	Company / relationship	Format	Current status / indication	Commercial relevance
TISSEEL	Baxter	Liquid	FDA licensed; adjunctive hemostasis in adult and pediatric surgery	Established broad hemostasis platform
ARTISS	Baxter	Liquid / adherence	FDA licensed; skin-graft and facial-flap adherence; not indicated for hemostasis	Differentiated reconstructive-surgery niche
VISTASEAL / VERASEAL	Instituto Grifols; distributed/marketed by Ethicon/J&J in key markets	Liquid; drip/spray	FDA licensed; pediatric indication expanded Sep. 2024	Plasma manufacturing + surgical distribution + applicator platform
EVARREST	Omrix; distributed by Ethicon	Patch	FDA licensed; adult adjunctive hemostasis with manual compression	Active patch competitor
TachoSil	Corza Medical	Patch	FDA licensed; cardiovascular and hepatic surgery; broader European uses	Manufacturing integrated in 2024; EQT acquisition pending
Beriplast / Beriplast P Combi-Set	CSL Behring	Liquid kit	Marketed in selected countries	Country-specific plasma portfolio
Vivostat Fibrin	Vivostat A/S	Autologous system	Patient-derived fibrin prepared at point of care	Equipment + recurring disposable model
ReliSeal	Reliance Life Sciences	Liquid kit	Human plasma-derived fibrin sealant; 0.5 mL and 1 mL packs	Regional pack-size and supply positioning
BOLHEAL	KM Biologics	Liquid / tissue sealant	Japanese plasma-derived tissue sealant	Domestic Japanese franchise
FIBINGLURAAS	Shanghai RAAS	Human fibrin sealant kit	Commercial product in China	Vertically integrated domestic plasma platform

Legacy status note: FDA continues to list EVICEL and RAPLIXA within its fibrin product category, but the Purple Book records their U.S. presentations as discontinued. EMA states that EVICEL’s EU authorization was withdrawn on 5 July 2024 at the marketing authorization holder’s request following a decision to permanently discontinue marketing for commercial reasons. [2] [9] [10] [11]

Baxter International
Baxter’s relevant fibrin portfolio is led by TISSEEL and ARTISS. TISSEEL addresses adjunctive surgical hemostasis, while ARTISS addresses skin-graft and tissue-flap adherence rather than general bleeding control. This separation gives Baxter access to both broad surgical and specialized reconstructive workflows. Baxter’s Advanced Surgery business generated USD 1.198 billion in 2025, but that public figure covers a wider portfolio of hemostats, sealants and adhesion-prevention products and is not used as a fibrin-sealant revenue estimate. [3] [4] [23]

 

Johnson & Johnson MedTech / Ethicon and Grifols
The VISTASEAL/VERASEAL platform combines Grifols’ plasma-protein manufacturing with Ethicon’s surgical commercialization and application technology. FDA lists Instituto Grifols as the VISTASEAL manufacturer, while the current package insert identifies Ethicon as distributor. Ethicon also distributes EVARREST, giving the company both liquid and patch positions. The 2024 VISTASEAL pediatric expansion and airless/laparoscopic applicators strengthen the platform through indication breadth and workflow rather than a new clotting mechanism. [5] [6] [7] [26] [36]

 

Corza Biosurgery
Corza’s position is centered on TachoSil, an absorbable fibrin patch with U.S. cardiovascular and hepatic indications and broader use in several international markets. Corza acquired TachoSil’s Linz manufacturing operations in July 2024 after previously acquiring commercial rights, integrating manufacturing priorities with commercialization. In July 2026, EQT agreed to acquire Corza Biosurgery; the transaction is expected to close in Q4 2026 and EQT has stated that it intends to invest in U.S. growth, indication and geographic expansion, innovation and complementary M&A. [8] [24] [25]

 

CSL Behring
CSL Behring participates through Beriplast and Beriplast P Combi-Set in selected international markets. CSL’s current global product list shows Beriplast P Combi-Set across countries in Latin America, Europe and Asia, making the portfolio regionally relevant but not a single globally uniform franchise. Its broader plasma-protein manufacturing infrastructure remains a strategic advantage in markets where local registration and supply continuity are important. [30]

 

Vivostat A/S
Vivostat competes through an autologous model rather than pooled donor plasma. Its system processes approximately 120 mL of a patient’s own blood and produces an autologous fibrin sealant or platelet-rich fibrin matrix in about 25 minutes without adding thrombin or bovine components. The business model combines processing/application equipment with recurring single-use preparation sets, making adoption most practical in centers with sufficient case volume and trained staff. [27]

 

Reliance Life Sciences, KM Biologics and Shanghai RAAS
Regional manufacturers add competitive depth outside the largest multinational platforms. Reliance Life Sciences markets ReliSeal in 0.5 mL and 1 mL packs in India; KM Biologics supplies BOLHEAL in Japan; and Shanghai RAAS markets the FIBINGLURAAS Human Fibrin Sealant Kit in China. These companies compete through local plasma infrastructure, country-specific hospital relationships, pack formats and domestic supply rather than through one global commercialization model. [28] [29] [31] [32]

 

Strategic Signals: Label Expansion, Manufacturing Control and Portfolio Rationalization

The most commercially important recent product event is VISTASEAL’s September 2024 U.S. pediatric indication expansion. FDA approved use in patients younger than 18 years, and the completed Grifols pediatric Phase 3 program compared the fibrin sealant with EVICEL in pediatric parenchymal and soft-tissue surgery. Grifols reported that the study enrolled 178 treated patients across 18 centers and achieved greater than 95% efficacy in both arms for hemostasis within four minutes. The program is now lifecycle evidence supporting a marketed product rather than an active pipeline asset. [6] [26] [35]

TachoSil is undergoing a different form of lifecycle development. Corza’s 2024 acquisition of the Linz manufacturing operation brought production and commercialization under common control, while EQT’s July 2026 agreement to acquire the biosurgery business introduces new capital and an explicit strategy around commercial acceleration, indication expansion, geographic growth and complementary acquisitions. For competitors, this raises the possibility of a more aggressively developed standalone patch platform after the transaction closes. [24] [25]

Portfolio exits are equally informative. FDA’s Purple Book records EVICEL and RAPLIXA U.S. presentations as discontinued, and EMA documents the 2024 withdrawal of EVICEL’s EU authorization for commercial reasons. These exits show that regulatory approval alone does not guarantee long-term commercial viability; manufacturing economics, differentiation, distribution support, hospital contracting and strategic portfolio priority remain essential. [9] [10] [11]

Public FDA, EMA and ClinicalTrials.gov sources reviewed through 31 August 2026 do not indicate a broad late-stage pipeline of novel fibrin-sealant molecules comparable with a pharmaceutical pipeline. Current innovation is concentrated in label expansion, pediatric use, patch engineering, applicators, minimally invasive delivery, pack configuration, autologous processing and portfolio consolidation. This is the appropriate pipeline lens for a mature biosurgery category.

 

2032 Outlook: Share-Shift Drivers, Substitution Risk and Commercial Priorities

The progression from USD 1.48 billion in 2025 to USD 2.39 billion by 2032 reflects targeted expansion in high-value surgical situations rather than universal fibrin-sealant use. Liquid systems will remain the largest revenue pool, but SMR expects spray-configured systems and patches to expand faster because they solve different workflow and surface-coverage problems. By application, neurosurgery and liver/transplant surgery carry the fastest supplied CAGRs, while Asia Pacific contributes the strongest regional growth rate.

The principal forecast constraint is substitution. Fibrin sealants compete with sutures, cautery, compression, tranexamic-acid protocols, oxidized cellulose, gelatin matrices, collagen-based products, polysaccharide powders and synthetic sealants. The 2022 Premier utilization analysis also shows that hospitals already use multiple topical hemostatic technologies across different specialties, reinforcing that this is a procedure-selection market rather than a single-product standard of care. [15]

Evidence quality will influence share shifts. In vascular and cardiac surgery, the systematic review supports faster hemostasis and lower blood loss but not lower transfusion or mortality. In facial plastic surgery, a 2025 database analysis covering 550,777 patients identified only 600 with recorded fibrin-sealant use and found no significant adjusted difference in overall complications. These findings do not invalidate fibrin sealants; they increase the commercial value of identifying the exact procedures, bleeding grades and care pathways in which product cost is justified. [17] [34]

For suppliers, the most defensible growth strategy is therefore procedure-specific rather than category-wide. Winning platforms will combine clinical evidence with easy preparation, low-waste pack sizes, reliable biologic manufacturing, minimally invasive delivery options and contracting that fits bundled hospital and ASC economics. In North America and Europe, differentiation is increasingly about evidence and workflow; in Asia Pacific, local plasma supply and domestic commercialization can be equally important. The companies most likely to gain share are those that can translate a fibrin mechanism into a clearly defined surgical and economic use case.

 

Strategic Market Research Methodology and Evidence Standards

Market sizing: The USD 1.48 billion 2025 market value, USD 2.39 billion 2032 forecast and 7.1% CAGR are Strategic Market Research estimates. All segment and regional shares, market sizes and CAGRs in this report are SMR inputs or calculations based on the supplied 2025 market baseline. No market-size, market-share or forecast figures from competing market research companies were used.

Scope control: SMR uses a narrow fibrin-sealant scope covering fibrinogen-thrombin liquid systems, spray-configured systems, active fibrin patches and operative autologous fibrin platforms. Non-fibrin topical hemostats and synthetic sealants are excluded. Product-type revenue is allocated by predominant commercial delivery configuration to avoid double counting products that can be both dripped and sprayed.

Evidence hierarchy: Product approval and status claims were checked against FDA, FDA Purple Book and EMA records. Clinical-trial status was checked against ClinicalTrials.gov and regulator documentation. Healthcare utilization and reimbursement context were drawn from AHRQ, NHS England, the German Federal Statistical Office, CMS and MedPAC. Company developments were supported with SEC filings and official company announcements. Peer-reviewed evidence was used to explain utilization, efficacy and health-economic context; company-funded research is identified where material.

SMR Executive Thesis

Fibrin sealants are evolving from a broad “biologic glue” category into a procedure-specific biosurgery market in which delivery format, clinical evidence, pack economics, indication breadth and supply control increasingly determine commercial value. Liquid products remain the revenue base, while spray-configured systems and patches are growing faster. The most important 2024–2026 competitive signals are the pediatric expansion of VISTASEAL, Corza’s integration of TachoSil manufacturing, EQT’s pending acquisition of the TachoSil biosurgery business, and the withdrawal or discontinuation of legacy EVICEL and RAPLIXA presentations. Asia Pacific is the fastest-growing region in SMR’s model, with local plasma manufacturers adding a different competitive dynamic from North America and Europe.

 

Fibrin Sealants Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.48 Billion
Revenue Forecast in 2032	USD 2.39 Billion
Overall Growth Rate	CAGR of 7.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Liquid Fibrin Sealants, Patch-Based Sealants, Sprayable Sealants
By Application	General Surgery, Cardiovascular Surgery, Orthopedic Surgery, Liver and Transplant Surgery, Neurosurgery
By End User	Hospitals and Surgical Centers, Specialty Clinics, Military and Field Hospitals
By Region	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Procedure-specific bleeding control, adoption of ready-to-use liquid and spray systems, faster growth of absorbable fibrin patches, pediatric label expansion, complex cardiovascular and transplant surgery, minimally invasive delivery, hospital workflow optimization, regional plasma manufacturing, and outpatient surgical expansion
Customization Option	Available upon request